

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

FRIGERIO ET AL.

U.S. APPLICATION NO: 10/531,515

35 USC §371 DATE: JUNE 16, 2003

FOR: MODULATION OF S6 KINASE ACTIVITY FOR THE TREATMENT  
OF OBESITY

**Mail Stop: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement of March 10, 2008, Applicants elect the claims of Group V, claims 12-17, drawn to a method for treating fat accumulation by administering an S6 kinase modulator. In addition, Applicants further elect subgroup (G) Modulator of enzyme activity. This election is made without traverse.

With the accompanying Petition for a One-Month Extension of Time, Applicants believe that this election is timely made. However, if it is deemed that additional fees are required, the Commissioner is authorized to charge Deposit Account No. 50-4409 in the name of Novartis for any additional fees due.

Applicants reserve the right to prosecute the subject matter of any non-elected claim groups in one or more divisional applications.


An early and favorable action on the merits is respectfully requested. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis Institutes for BioMedical Research, Inc.  
400 Technology Square  
Cambridge, MA 02139

(617) 871-3346

Date: April 14, 2008

  
John Prince  
Attorney for Applicant  
Reg. No. 43,019